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INTRODUCTION 
 
“Lymphomas are malignant neoplasms of lymphoreticular system” as quoted by 
John K C Chan in the book ‘Diagnostic histopathology of tumors’ [1]. They 
present as a solid mass generally. The incidence of this tumor is increasing 
worldwide as well as in India and is not a rare tumor anymore. The national 
cancer registry programme in its first all India report in the year 2001-2002 
claims an incidence of 5.1 per one lakh population. [2] 
Painless lymph node enlargement confined to one lymph node region or 
involving multiple lymph node regions is the commonest clinical presentation 
of a lymphoma. Apart from the nodes, lymphomas can involve skin, 
gastrointestinal tract, salivary glands, nasopharynx, paranasal sinuses, lung, 
thyroid, ocular adnexa, kidneys, adrenals, breast etc. When the lymphomas 
involve the sites other than the nodes they are called extranodal lymphomas. [1] 
Lymphomas when suspected clinically needs to be confirmed histologically. A 
confirmatory diagnosis of lymphoma is made by a histological examination, 
sometimes aided by ancillary techniques like immunohistochemistry, flow 
cytometry and genetic studies. The lymphomas can be broadly categorised as 
Hodgkin’s lymphoma (HL) and Non Hodgkin’s lymphoma (NHL). Based upon 
the principles adopted in REAL classification, WHO has classified about 58 
lymphomas under the following six broad groups. [3] 
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• Precursor lymphoid neoplasm  
• Mature B cell neoplasms. 
• Mature T cell and natural killer (NK) cell neoplasms 
• Hodgkin lymphoma  
• Histiocytic and dendritic cell neoplasm  
• Post transplant lymphoproliferative disorders 
With the existence of this vast range of lymphomas it is quite essential to 
diagnose the specific type of lymphoma as they all have different clinical 
outcomes and different modes of treatment. Diagnosing the type of lymphoma 
and subcategorizing them is challenging as most of them have an overlapping 
morphology making it practically difficult to diagnose the type based upon the 
morphology alone. Hence the aid of ancillary techniques like flow cytometry and 
IHC becomes essential. IHC is a reliable and most commonly used technique in 
these situations. IHC has many roles in a case of lymphoma, but the most 
important role of IHC is in establishing the cell lineage. PAX5 is one such IHC 
marker helpful in establishing the cell lineage and thereby aid in diagnosing the 
specific subtype of lymphoma. 
PAX5 gene is a member of the paired box gene family and is located in 
chromosome 9p13. It encodes the transcription factor, PAX5, also known as B 
cell specific activator protein (BSAP). It is expressed in B lymphocytes from 
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pro B cells to mature B cells and is essential for B cell development and 
differentiation  and is reliably detected by immunohistochemistry.[4] PAX5 
expression is specific for B cells especially in the precursor stage where CD20 
is negative. Thereby detection of PAX5 expression in lymphomas is a useful 
tool for diagnosis and in sub classification of lymphomas. [5][6]  
Therefore, we propose to do a retrospective study to assess the PAX5 
immunoreactivity as a B cell lineage marker in the samples received as 
lymphoid malignancies during the period of 2009 to 2010 and to correlate with 
the other routinely used CD markers in cases of lymphoma.  
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AIMS AND OBJECTIVES 
 
• To assess the expression of PAX5 in lymphomas and to correlate it with the 
other pan B cell markers. 
• To correlate it with various clinical parameters and other panel of markers for 
lymphoma 
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REVIEW OF LITERATURE 
Lymphomas are the malignant neoplasms arising from the cells of immune 
system or the lympho-reticular system.[1] They present as solid masses, unlike 
leukemia, which also have the similar origin but involves the bone marrow 
and/or peripheral blood. A global study on incidence and survival rates of 
various cancers across different global areas done by Parkin DM et al estimated 
2,80,000 new cases of lymphomas contributing 3.4% of the total cancer 
incidence. Lymphomas are responsible for about 2.9% of all cancer related 
deaths globally. The incidence of lymphomas was very less in the south central 
Asia when compared to the rest of the world and the maximum number of cases 
was reported from western countries, Africa and Australia. [7]  
Although the incidence of lymphoma is low in India, the five year survival 
rate is markedly less when compared to the developed countries. The incidence 
of lymphomas is increasing throughout the world as well as in India. As per the 
national cancer registry programme: first all India report 2001-2002 the 
incidence of lymphoma was 5.1 per 1,00,000.[2] Balakrishna B Yeole et al 
studied the incidence of Non Hodgkin Lymphoma (NHL)  in all the major 
registries in India and observed a significant increase in the incidence of NHL 
over the years in all the registries.[8]  This increasing incidence rates and poor 
survival makes lymphoma a major concern. In order to facilitate the study of 
epidemiological and clinic-pathological aspects of lymphomas in India , a 
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Lymphoma registry has been established in Tata Memorial Hospital, Mumbai.[9] 
The increasing incidence rate is in part contributed by improving diagnostic 
methods, evolving criteria for lymphomas, increased incidence in AIDS and 
AIDS associated lymphomas. Balakrishna B Yeole suggests an extensive study 
to ascertain the influence of the above mentioned factors on the increasing 
incidence rates. [8] 
Lymphomas show a definite male predominance throughout the world.[7] 
The age group commonly involved vary with the type of lymphoma. Hodgkin 
Lymphoma (HL) shows a peak incidence between 11-30 years and between 51-
60 years. NHL consists of numerous histologic subtypes and the age groups 
involved understandingly vary. In general, NHL are more common after 50 
years of age.[1] A study of HL and NHL in rural India done by Sudipta 
Chakraborti et al also found a similar age distribution for HL, but NHL seemed 
to involve younger patients when compared to the rest of the world.[10] 
A non tender enlarged lymph node, involving a single or multiple groups is 
the most common presentation of lymphoma. They can virtually involve any 
site, and commonly involved sites other than lymph node are skin, gastro 
intestinal tract (GIT), salivary glands, spleen, tonsils, sinuses, brain, lung etc. 
Lymphomas involving sites other than lymph nodes are called extra-nodal 
lymphomas.[11][1] They can secondarily involve the bone marrow or spill into the 
peripheral blood and present as leukemia.[11] In addition to the 
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lymphadenopathy they can have other symptoms like fever, weight loss, 
anorexia, dyspnoea, abdominal/ chest pain, compressive symptoms, pruritus or 
even bleeding. There could be an enlarged liver or spleen and anemia associated 
with lymphomas.[10] They are prone to infections due to loss of immunity. The 
patients also have predilection to develop auto immune diseases owing to 
immune modulation and the vice versa is also true. [11]  
EVOLUTION OF CLASSIFICATION OF LYMPHOMAS: 
The first case of lymphoma was identified by Thomas Hodgkin while working 
at the Guys hospital, London in the year 1832. He published his paper on 
lymphatic disease “On some morbid appearances of absorbent glands and 
spleen”. His observations consented with those of Samuel Wilks, who named 
this condition as Hodgkin’s disease, paying credit to Thomas Hodgkin. It was in 
1898 and 1902, when Carl Sternberg and Dorothy Reed gave the most 
important diagnostic entity for Hodgkin’s disease by defining the classical 
Reed-Sternberg cell (RS cell).  Variants of RS cells were later identified. [12] 
HD was believed to be a benign process progressing into malignancy. The first 
classification of HD introduced in the year 1944 by Jackson and Parker was 
based upon this concept.  Later in 1966, Lukes and Butler introduced a 
classification of HD which was shortly revised at Rye conference, where it was 
accepted to classify HD into 4 subtypes. This classification had a good 
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correlation with the survival and outcome, making it popular among the 
clinicians.[12] 
The application of immunohistochemical methods for studying various diseases 
came into light in 1970s. The advent of the immunologic methods resulted in 
better understanding of the disease process, recognition of new neoplasms and 
eventually influenced the classification of many tumors. The RS cells and its 
variants showed positivity for CD15 and CD 30 in most of the cases, but there 
were a considerable number of cases which were negative for these markers. 
These cases showed similarity in clinical and morphological features. The 
Revised European American classification of lymphomas (REAL) introduced in 
the year 1994, took into consideration the immunological and genetic features in 
addition to morphology.[13] They categorized HL into classical HL (CHL), 
which are positive for CD15, CD30 and nodular lymphocyte predominant HL 
(NLPHL), which are negative for the above markers. The CHL was again 
categorized into 4 subtypes. The present WHO classification of lymphoma 
adapts the REAL classification for HL, with a slight modification of including 
unclassified category under CHL. The following table shows the various 
classifications used for HL over the years. [12]\ 
 
 
9 
 
 
 
YEAR 
NAME OF THE 
CLASSIFICATION 
 
CLASSIFICATION 
  
 
 
 1944 
 
 
Jackson – Parker 
 
Paragranuloma 
Granuloma 
Sarcoma 
 
 
 
1966 
 
 
Rye conference 
 
 Lymphocyte predominant 
       Nodular sclerosis 
              Mixed cellularity 
              Lymphocyte depleted 
 
 
 
 
 
 
1994 
 
 
 
 
 
REAL    
           
            Classical HL 
            Nodular sclerosis 
            Lymphocyte rich 
            Mixed cellularity 
            Lymphocyte depleted 
Nodular lymphocyte predominant            
HL(NLPHL) 
 
 
 
2008 
 
 
 
WHO  
Classical HL 
Nodular sclerosis 
Lymphocyte rich 
Mixed cellularity 
Lymphocyte depleted 
unclassifiable 
    Nodular lymphocyte predominant 
HL(NLPHL) 
 
 
TABLE  1:     VARIOUS TYPES OF CLASSIFICATION ADOPTED         
FROM 1944 TO 2008 
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The evolution of the classification of the NHL is a little more complex than that 
of the HL. Ever since the identification of HD, numerous neoplasms arising 
from the lymphocytes were identified, which were different from the HL in 
terms of morphology and clinical picture. These tumors were categorized as 
Non Hodgkin Lymphoma (NHL), simply implying that these tumors are 
lymphomas other than Hodgkin’s lymphoma. 
At first, attempts were made to classify NHL based upon the differentiation. 
Differentiation refers to the degree of resemblance to the normal counterpart. 
Hence in 1966, Henry Rappaport classified the NHL into lymphocytic, 
histiocytic, mixed type and undifferentiated types. The lymphocytic type was 
again classified into poorly differentiated and well differentiated subtypes. With 
improved understanding of lymphomas, the term histiocytic used in this 
classification was found to be erroneous as they do not represent the tumors 
arising from histiocytes. Hence an improved classification became 
mandatory.[14] 
In 1982, a working formulation of NHL was introduced categorizing the NHLs 
into low grade, intermediate grade, high grade and miscellaneous. This 
classification was welcomed by the clinicians and was in use for a long time 
since this way of classifying lymphomas also indicates the prognosis. 
The advent of immunological methods encouraged the classification of 
lymphomas based upon the cell type. An updated Kiel classification was 
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introduced in 1989 and was followed in many European countries, though the 
Americans retained the use of working formulation for classifying lymphomas. 
It classified NHL into B and T cell lymphomas, which in turn were again 
classified into low grade, high grade and rare tumors.[14] 
In 1994, an international lymphoma study group proposed the Revised 
European American classification of lymphomas (REAL) in order to achieve 
consensus between the European and American nations. It took into 
consideration the morphologic, immunologic and genetic characteristics of the 
lymphomas.[13] The lymphomas were classified as B cell neoplasms, T cell 
neoplasms and Hodgkin disease. The B and T cell neoplasms were again 
classified into precursor neoplasms and peripheral neoplasms.  
WHO classification of the hematopoietic and lymphoid neoplasms proposed in 
the year 2003 took into consideration all the classifications used in various parts 
of the world and sought the opinion of renowned clinicians across the globe. 
This was the first classification to be agreed throughout the globe. The current 
WHO classification is a revision of the 2003 classification. It provides a 
separate category for lymphomas which cannot be classified under a specific 
category, thereby making it easy to recognize the cases which require further 
study. 
 The current WHO classification of hematopoietic and lymphoid neoplasms, 
2008 classifies lymphomas under the following 6 broad groups: [3] 
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 Precursor lymphoid neoplasm  
 Mature B cell neoplasms. 
 Mature T cell and natural killer (NK) cell neoplasms 
 Hodgkin lymphoma  
 Histiocytic and dendritic cell neoplasm  
 Post transplant lymphoproliferative disorders. 
The following table no :2  gives the detailed classification of both NHL and HL 
adopted by WHO in 2008. 
 
 
  
 
 
PRECURSOR LYMPHOID 
NEOPLASMS 
• B lymphoblastic lymphoma, NOS 
• B lymphoblastic lymphoma with 
recurrent genetic abnormalities 
• B lymphoblastic lymphoma with t(9;22) 
• B lymphoblastic lymphoma with MLL 
rearranged 
• B lymphoblastic lymphoma with 
t(12;21) 
• B lymphoblastic lymphoma with 
hyperdiploidy 
• B lymphoblastic lymphoma with 
hypodiploidy 
• B lymphoblastic lymphoma with t(5;14) 
• B lymphoblastic lymphoma with t(1;19) 
• T lymphoblastic lymphoma 
  
TABLE 2: WHO CLASSIFICATION OF LYMPHOMAS 2008 
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MATURE B CELL 
NEOPLASMS 
 
• Small lymphocytic lymphoma 
(SLL/CLL) 
 
• B cell prolymphocytic leukemia 
• Splenic B cell marginal zone lymphoma 
• Hairy cell leukemia 
• Splenic B cell lymphoma 
• Lymphoplasmacytic lymphoma (LPL) 
• Heavy chain diseases 
• Plasma cell myeloma 
• Solitary plasmacytoma of bone 
• Extra-osseous plasmacytoma 
• Extranodal marginal zone lymphoma of 
mucosa associated lymphoid tissue 
(MALT lymphoma) 
• Nodal marginal zone lymphoma (MZL) 
• Follicular lymphoma (FL) 
• Primary cutaneous follicle centre 
lymphoma 
• Mantle cell lymphoma 
• Diffuse large B cell lymphoma 
(DLBCL) 
• DLBCL associated with chronic 
inflammation 
• Lymphomatoid granulomatosis 
• Primary mediastinal large B cell 
lymphoma 
• Burkitt lymphoma 
• B cell lymphoma , unclassifiable,with 
feature intermediate between DLBCL 
and Burkitt lymphoma 
• B cell lymphoma, unclassifiable, with 
features intermediate between DLBCL 
and classical HL  
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MATURE T CELL AND NK 
CELL NEOPLASMS 
• T cell prolymphocytic lymphoma 
• T cell large granular lymphocytic 
lymphoma 
• Aggressive NK cell leukemia 
• Systemic EBV positive T cell 
lymphoproliferative disease of 
childhood 
• Hydroa vacciniforme like 
lymphoma 
• Adult T cell lymphoma 
• Extranodal T cell lymphoma, nasal 
type 
• Enteropathy associated T cell 
lymphoma 
• Hepatosplenic T cell lymphoma 
• Subcutaneous panniculitis like T 
cell lymphoma 
• Mycosis fungoides 
• Sezary syndrome 
• Primary cutaneous CD30 positive 
T cell lymphoproliferative 
disorders 
• Lymphomatoid papulosis 
• Primary cutaneous peripheral T cell 
lymphomas, rare types 
• Primary T cell lymphoma, NOS 
• Angioimmunoblastic T cell 
lymphoma 
• Anaplastic large cell lymphoma, 
ALK positive 
• Anaplastic large cell lymphoma, 
ALK negative 
HODGKIN LYMPHOMA (Classified as described earlier) 
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HISTIOCYTIC AND 
DENDRITIC NEOPLASMS 
• Histiocytic sarcoma 
• Langerhans cell histiocytosis 
• Langerhans cell sarcoma 
• Interdigitating dendritic cell 
sarcoma 
• Follicular dendritic cell sarcoma 
• Fibroblastic reticular cell tumor 
• Indeterminate dendritic cell tumor 
• Disseminated juvenile 
xanthogranuloma 
 
POST TRANSPLANT 
LYMPHOPROLIFERATIVE 
DISORDER (PTLD) 
• Polymorphic PTLD 
• Monomorphic PTLD 
• Classical HL type PTLD 
• Plasmacytic hyperplasia and 
infectious mononucleosis like 
PTLD 
 
Once a lymphoma is diagnosed and is classified under a specific category, it 
needs to be staged like any other neoplasm. The Ann-Arbor staging system 
has been in use for staging both the HL and NHL.[1][11] In addition to the 
history of illness, physical examination and radiological data are essential for 
staging the disease. A minimum of ultra sonogram of abdomen has to be done 
in order to stage the disease efficiently. [14] The staging system stratifies 
lymphomas into four stages, from stage I to stage IV. A letter ‘E’ is added to 
this stage in case the primary tumor is in an extra-lymphoid organ, which are 
the organs other than lymph node, spleen, thymus, Waldeyer’s ring, appendix 
and Peyer’s patches. These stages are again sub-classified based upon the 
presence (B) or absence (A) of systemic symptoms like 
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 Unexplained fever 
 Unexplained weight loss of more than 10% of body weight in 
preceding 6 months 
 Night sweats 
The following table 3 illustrates the Ann-Arbor staging.[1] 
 
 
 
STAGE I 
Involvment of a single lymph node or a single 
extralymphoid organ 
 
STAGE II 
Involvement of two or more lymph node regions on the same 
side of the diaphragm or localized involvement of an 
extralymphatic organ  and one or more lymph node regions on 
the same side of the diaphragm 
 
STAGE III 
Involvement of lymph node regions on both side of the 
diaphragm, which may also be accompanied by localised 
involvement of an extralymphatic organ or involvement of 
spleen or both 
 
STAGE IV 
Diffuse or disseminated involvement of one or more 
extralymphatic organs or tissues with or without associated 
lymph node enlargement 
 
SUBCLASSIFICATION: 
 
A- Without the symptoms listed below 
B- With systemic symptoms 
 Unexplained fever  
 Unexplained weight loss of more than 10% of body weight in preceding 
6 months  
 Night sweats 
 
TABLE 3:   ANN – ARBOR STAGING FOR LYMPHOMAS
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The accurate diagnosis of lymphoma can only be made with adequate clinical 
history. Some of the lymphomas have certain clinical findings reserved to 
them and aid in the diagnosis. The important clinical findings that are 
essential in the diagnosis of lymphoma include 
 Age 
 Sex 
 Site 
 Duration 
 Presence of B symptoms 
 Presence of lymphadenopathy 
 Associated organomegaly 
 History of treatment  
 Skin lesions 
 History of associated infections like HIV, HBV, HCV etc. 
The clinical picture not only drives a pathologist towards a diagnosis but also 
helps the pathologist to assess the optimal ancillary technique that will be 
required in a particular case. 
HISTOLOGY OF A NORMAL LYMPHNODE: 
A thorough knowledge about the histology of the lymph node is mandatory 
before assessing a case of lymphoma. This is because certain lymphomas 
have characteristic pattern of involving the lymph node and the lymphomas 
as such are presumed to resemble the normal counterparts of the cells in 
18 
 
lymph node, and hence named after them.[15] For example marginal zone 
lymphoma and mantle cell lymphoma are named so because of their 
resemblance to marginal zone cells and mantle cells of a normal lymph node 
respectively. Knowing the histology of lymph node also helps in 
understanding the pattern of immunohistochemical markers in a normal 
lymph node.  
Lymph nodes are encapsulated, bean shaped, firm structures, whose size vary 
with site and activity. The afferent lymphatics enter through the convex 
surface and the efferent lymphatics and veins leave through the hilum. 
Ateries and nerves enter through the hilum.  The lymph node is composed 
mainly of three regions, which are:[16][17] 
 Cortex  
 Medulla  
 Paracortex  
The cortex is identified by the presence of lymphoid follicles with cortical 
sinuses running between them. The follicles can be primary follicles or 
secondary follicles. The secondary follicles have a germinal centre, 
surrounded by a mantle zone which in turn is surrounded by a marginal zone. 
Follicular dendritic cells and tingible body macrophages are present in the 
germinal centre in addition to the lymphoid cells. The lymphoid cells are 
predominantly B cells admixed with a few T cells. The B cells in the follicles 
are either centroblasts or centrocytes. Centroblasts have a vesicular nuclei 
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and amphophilic cytoplasm whereas centrocytes have a cleaved nuclei, dense 
chromatin and scant cytoplasm. The cells of the primary follicles and the 
mantle zone are small and have dense chromatin and the cells in the marginal 
zone are similar but slightly larger and have more cytoplasm. [16][17] 
The medulla is made up of cords of cells, mainly plasma cells with 
intervening medullary sinuses which contain histiocytes. 
The region between the cortex and medulla is called paracortex. This region 
is highly vascular and is rich in T lymphocytes. [16][17] 
We need to bear in mind that the architecture of the lymph node is not static 
and it changes with different stimuli. The lympnodes from different sites 
show different morphology. For example the abdominal nodes show a 
prominent marginal zone. This should not be confused with a reactive or 
neoplastic process. The following figure (fig:1) depicts the structure of a 
lymph node as in google images site//www.dartmouth.edu/... in the article 
overview of  the lymphoid immune system[18] 
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                   Figure 1: STRUCTURE OF A LYMPHNODE 
 
 
 
MORPHOLOGICAL APPROACH TO LYMPHOMA: 
In almost all the cases of nodal lymphomas, the normal structure of the lymph 
node is completely or partly replaced with the neoplastic cells. Some of the 
lymphomas like follicular lymphoma (FL) do not disturb the normal structure 
of a lymph node and hence can be confused with a reactive process. FL can 
be differentiated from a reactive follicular hyperplasia by the presence of 
prominent mantle zone. Viral infections can show numerous immunoblasts 
that can be confused with RS cells. Histiocyte rich areas in Kikuchi’s 
lymphadenitis and necrotic areas can lead to considering a DLBCL in the 
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differential diagnosis. Therefore we need to bear in mind all the reactive 
conditions that simulate a lymphoma before making a diagnosis of 
lymphoma.[1] 
Once all the reactive conditions have been ruled out, the pattern of the 
lymphoma needs to be assessed. Different lymphomas have a different 
pattern of involvement and are characteristic to the type of lymphoma. The 
commonly seen patterns in a lymphoma include 
 Nodular 
 Mantle zone  
 Marginal zone 
 Sinusoidal  
 Starry  sky 
 Interfollicular  
 Vascular  
 Diffuse  
Nodular pattern of involvement is seen in cases like follicular lymphoma and 
nodular type of mantle cell lymphoma or marginal zone lymphoma. NLPHL 
and nodular sclerosis type of classical HL also show a nodular pattern. These 
nodules are separated by dense fibrous tissue. Sometimes ALCL also has this 
pattern of involvement. The presence of RS cells or L and H cells aid in its 
diagnosis of HL. The nodules formed by small lymphocytic lymphoma and 
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rarely by lymphoplasmacytoid lymphoma are vague and are also called 
pseudonodular or pseudofollicular pattern.[1] 
Mantle zone and marginal zone pattern are seen in mantle cell lymphoma and 
Marginal zone lymphoma repectively. Starry sky pattern, called so due to the 
presence of numerous tingible body macrophages interspersed with them is 
characteristic feature in Burkitt’s lymphoma. This pattern is also noted in 
lymphoblastic lymphoma.[1] 
Lymphomas like ALCL, mycosis fungoides etc can be seen involving only 
the sinuses and spread along the sinuses. Carcinomas metastasizing to the 
lymphnodes also involve the sinuses first. Hence care should be taken to 
avoid misdiagnosis. An interfollicular pattern of involvement is seen 
commonly in the T cell lymphomas. Some lymphomas like have a prominent 
vascular proliferation. This vascular pattern in commonly seen in 
angioimmunoblastic T cell lymphomas and peripheral T cell lymphomas. A 
diffuse pattern of involvement is seen in almost all types of lymphomas. The 
following table (table 4) shows the common pattern of involvement seen in 
various lymphomas 
 
 
 
 
 
23 
 
 
 
PATTERN LYMPHOMA 
 
 
Nodular 
• Follicular lymphoma 
• Mantle cell lymphoma 
• Marginal zone lymphoma 
• NLPHL 
• Nodular sclerosis HL 
• Small lymphocytic lymphoma 
• Lymphoplasmacytoid lymphoma 
• Anaplastic large cell lymphoma 
 
Mantle zone Mantle cell lymphoma 
Marginal zone Marginal zone lymphoma 
Starry sky pattern Burkitt’s lymphoma 
Lymphoblastic lymphoma 
Sinus pattern Anaplastic large cell lymphoma 
Mycoises fungoides 
Marginal zone lymphoma 
Interfollicular 
pattern 
T cell lymphomas 
Vascular pattern Angioimmunoblastic T cell lymphoma 
Peripheral T cell lymphoma NOS 
 
After identifying the pattern, the morphology of individual cells needs to be 
examined, starting from the size of the cells. The cells can be divided into 
three types: 
 Small cells 
TABLE 4: VARIOUS PATTERNS AND TYPES OF LYMPHOMA 
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 Medium sized cells  
 Large cells 
The cells are compared with the size of the endothelial cells. The cells 
smaller than endothelial cells are called small cells and those larger than them 
are called large cells. The cells which are just about the size of the endothelial 
cells are called medium sized cells. Other fine details like the shape of the 
nucleus and chromatin pattern are also observed. The small cells are seen 
commonly in follicular lymphoma and mantle cell lymphoma while the large 
cell morphology is seen in ALCL, DLBCL and plasmablastic lymphoma.  
The neoplastic cells can be admixed with a reactive cell population. 
Identifying the reactive population helps in the diagnosis. These cells in the 
background form the basis for classifying HL.[1] 
The following figure 2 summarises the approach to a case of lymphoma in 
the routine H and E slide.  
25 
 
FIGURE 2: ALGORITHM OF APPROACH TO A CASE OF LYMPHOMA 
 
  
ARCHITECTURE OF THE LYMPH NODE 
PRESERVED EFFACED 
MOST PROBABLY LYMPHOMA 
IDENTIFY THE PATTERN OF INVOLVEMENT 
ASSESS MORPHOLOGY OF THE CELLS AND 
THEIR NUCLEAR CHARACTERITICS 
IDENTIFY THE CELLS IN MICROENVIRONMENT 
REACTIVE PROCESS 
(FL CAN SHOW 
PRESERVED 
ARCHITECTURE)  RULE OUT REACTIVE CONDITIONS 
MIMICKING LYMPHOMA LIKE 
KIKUCHI’S 
LYMPAHADENOPATHY, VIRAL 
LYMPHADENOPATHY, 
DERMATOPATHIC 
LYMPHADENOPATHY ETC. 
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IMMUNOHISTOCHEMISTRY: 
Immunohistochemistry is a method of identification of the cellular 
constituents with the help of antigen antibody reaction.[19] It is based on the 
principles used for immunofluorescence, but does not require a specialized 
microscope for assessing the antigen antibody reaction. Antigens labelled 
with enzymes which produce a colourful reaction on addition of a chromogen 
is used in place of a fluorescent dye labelled antibodies in 
immunofluorescence.  
Flow cytometry is another technique that can be used for immunophenotypic 
analysis. But it requires sophisticated machinery and fresh specimen. Though 
IHC was initially practised on fresh and frozen specimens, with the advent of 
antigen reviving techniques and development of antibodies which can be used 
on paraffin embedded tissues, IHC can now be reliably practised on routine 
paraffin sections.[20][21][22] The morphology of the cells cannot be assessed in 
flow cytometry. IHC has the added advantage of morphological analysis and 
immunological analysis simultaneously. Hence IHC is superior to flow 
cytometry in certain conditions, especially lymphomas.[20] In addition, IHC 
facilitates the identification of the antigen antibody reaction at the sub 
cellular level i.e. the membrane, nucleus, Golgi apparatus etc.[19] 
  
 The IHC markers can be categorized into three types, based upon their use as 
follows: 
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 Diagnostic markers 
 Predictive markers  
 Prognostic markers 
Diagnostic markers are those which help in making diagnosis, like in case of 
a poorly differentiated tumour and in differentiating various other neoplasms 
from the normal or reactive process. Predictive markers are those which help 
in assessing the response to an available treatment. They predict the outcome 
of a therapeutic method and hence they are called so. Prognostic markers are 
those markers which help in determining the aggressiveness of the neoplasm 
and patient’s survival.[23] 
The majority of IHC markers used in lymphomas are for the leucocyte 
differentiation antigen and have an acronym CD which stands for ‘cluster of 
differentiation’. It was standardised to use this acronym followed by a 
number that corresponds to the small region, called epitope on the antigen, in 
order to overcome the confusion arising due to the different names used for 
the same marker by different investigators. The monoclonal antibodies are 
directed against the epitopes.[20] 
VALUE OF IHC IN LYMPHOMAS: 
Diagnosing a case of lymphoma and subtyping the lymphoma is one of the 
most challenging tasks for a pathologist. Lymphoma can be easily confused 
with other nonlymphoid neoplasms like poorly differentiated carcinomas, 
small cell/ neuroendocrine carcinomas, peripheral neuroectodermal tumors 
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(PNET), desmoplastic small round cell tumor (DSRCT), 
rhabdomyosarcoma, Wilms tumor etc. A positive reaction with CD45, also 
known as leucocyte common antigen helps in establishing the diagnosis as 
lymphoma and rules out the other possibilities.[19] 
There is a myriad of reactive conditions which mimic the lymphomas. IHC 
plays an important role in differentiating reactive process from a lymphoma. 
Even cases of HL can be confused with reactive node when the diagnostic 
Reed-Sternberg cells are scarce. IHC staining with CD15 and CD30 can help 
in establishing the diagnosis.  The pattern of IHC staining is also helpful to 
differentiate the lymphomas from a reactive process. For example in a case 
of follicular lymphoma, Bcl-2 is negative in the follicular centre, whereas it 
is positive in a reactive lymph node. 
Once a diagnosis of lymphoma is made, it needs to be categorised as HL or 
NHL, followed by placing it under a particular subtype. Morphology in 
adjunct with IHC is sufficient to type most of the lymphomas. The Non 
Hodgkin’s lymphoma project observed a significant increase in accurate 
diagnosis and sub-classification of lymphoma using IHC.[24] Some of the 
lymphomas have characteristic immunophenotypes that the presence of such 
immunophenotype is essential for making that diagnosis. 
Though HL can be diagnosed with the presence of Reed-Sternberg cell, it can 
be confused with diffuse large B cell lymphoma (DLBCL) when they are 
abundant. A uniform strong positivity with CD20 in DLBCL helps in 
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distinguishing them from HL. Nodular lymphocyte predominant Hodgkins 
lymphoma (NLPHL) with a predominant T cell population in the reactive 
component brings T cell rich B cell lymphoma into the differential diagnosis. 
In such cases, CD57+ve, CD4+ve T cell rimming around the 
Lymphohistiocytic cell (L H cell) helps in recognising them as NLPHL. 
Anaplastic large cell lymphoma (ALCL) is another lymphoma having cell 
that resemble the RS cells, but these cases are positive for ALK, clusterin and 
fascin. Certain antigens are preserved even in some necrotic tissues and IHC 
can be helpful in detecting these antigens in biopsies containing large areas of 
necrosis.[25] 
In case of NHL, the lineage of the lymphoma needs to be recognised. IHC 
markers are essential for establishing the lineage. CD20, CD79a, CD19 etc 
are commonly used for determining B cell lineage. All these markers can be 
used on paraffin embedded sections except CD19. The clonality of the B cell 
neoplasm can be established with the use of immunohistochemical staining 
with kappa and lambda light chains.  CD3 is the frequently used pan T cell 
marker. [25] 
Further characterisation of the neoplastic cells may be required after the 
recognition of the lineage. In case of B cell lymphomas CD5, CD10, CD23, 
BCL2 and BCL6 have been used and in case of T cell lymphomas CD2.CD4, 
CD5, CD7 and CD8 are used for this purpose. The absence of staining with 
pan T cell marker and altered CD4:CD8 ratio suggests a T cell lymphoma. [25] 
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The following figures (figure3 and 4) shows the use of IHC markers in 
diagnosing lymphomas and sub-categorizing them. 
FIGURE 3:  Role of IHC markers in subtyping Hodgkin lymphomas 
 
  
 
 
 
 
   
 
 
 
 
 
  
 
 
 
 
 
 
MORPHOLOGY OF LYMPHOMA 
UNDER H AND E 
PRESENCE OF CLASSICAL RS 
CELLS OR ITS VARIANTS 
SUGGESTIVE OF HL
STAINING WITH 
CD15 AND CD30
POSITIVE
HL CONFIRMED 
NEAGTIVE
CONSIDER NLPHL 
IDENTIFICATION OF 
THE REACTIVE 
POPULATION TO 
CLASSIFY HL 
CD57+VE CD4+VE 
CELLS RIMMING 
THE LH CELLS  
CONFIRM 
NO RIMMING 
WITH CD57+VE , 
CD4+VE CELLS 
CONSIDER NHL LIKE ALCL, 
DLBCL OR T CELL RICH B CELL 
LYMPHOMA 
31 
 
 
FIGURE 4:  Role of IHC markers in subtyping non Hodgkin lymphomas 
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IHC markers can also be used to assess the prognosis in lymphomas. DLBCL 
cases showing positive reaction with Bcl2, MUM1, FOXP1 and negative 
reaction with CD10 were found to have a bad prognosis. ALK positive cases of 
ALCL carry a good prognosis. Ki67/ MIB1 staining shows the proliferation 
index.[23] Lymphomas with high proliferation index have a bad prognosis. 
Reinhard Von Wasilewski et al observed that cases of HL that lack the 
expression of CD15 showed a bad prognosis.[26] 
The identification of the cell antigens has become more important ever since the 
successful introduction of Rituximab in the treatment of lymphomas. Rituximab 
is an anti CD20 therapy targeted against the cells having this surface antigen. 
The success of Rituximab has driven the investigators to identify other 
therapeutic targets. The drugs targeting other cell antigens like CD22, CD30, 
CD40, CD80 are still in the research process.[23] 
Thus immunophenotypic analysis in addition to being an integral part of WHO 
classification is also essential in making the correct diagnosis and assessing the 
prognosis. Though IHC plays a vital role in diagnosing lymphomas, 
morphological assessment still remains essential. IHC markers should be used 
cautiously and judiciously. A single marker is never sufficient in a case of 
lymphoma. Hence a panel of markers is almost always necessary.[25] The panel 
of markers commonly used in a case of lymphoma include: 
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 CD45 – to confirm the diagnosis of lymphoma (CD 45 is negative in 
classical HL and NK cell phenotype of ALCL) 
 CD3 – pan T cell marker 
 CD20- pan B cell marker 
 CD15 and CD30 – for diagnosing HL. 
CD45: 
CD45, also referred to as leucocyte common antigen (LCA) is a tyrosine 
phosphatase present on the surface of the leucocytes. CD45 is lost in plasma 
cells.[27] This antigen is rarely present in the Golgi apparatus in addition to the 
cell membrane. Some isoforms of CD45 are specific to certain cells. For 
example CD45RO is specific for T cell, histiocytes and CD45RA is seen 
predominantly in T cells.[1][27] CD45RB is the commonly used isoform as it is 
present in all leucocytes. Its primary role is to identify a lymphoma and to 
differentiate it from other tumors resembling lymphoma. CD45 expression is 
lost in classical HL and in cases of ALCL with NK cell phenotype. [1] 
CD3: 
CD3 is also referred by different names like Leu 4, T3 etc... [21] It is the T cell 
receptor protein complex composed of gamma, delta and epsilon chains. CD3 is 
initially positive in the cytoplasm and is transferred to the cell membrane with 
maturation. CD3 is negative in NK cells, though a cytoplasmic positivity can be 
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seen in some NK cells. [15] CD 3 is preferred over other T cell markers because 
of its specificity and easy, reliable detection on paraffin embedded sections.[27] 
The following figure 5 illustrates the various CD markers expressed during 
various stages of maturation of T cells. 
Figure 5: T cell development with the respective immune profile 
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CD20 is also known by other names like Leu26 and B1.[21] It is a 
nonglycosylated phosphoprotein seen on cell membrane surface of all the 
mature B cells. Its expression is seen from the pre B cell stage of maturation and 
is lost in plasma cell stage. The following flow chart shows the expression of 
various CD markers during the development of B cells. 
Figure 6: B cell development with the respective immuomarker profile 
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CD20 is expressed in all the mature B cell lymphomas. It is expressed in a part 
of classical HL and is seen in all NLPHL.[12][28] Rare CD20 expression is seen in 
some T cell lymphomas 
CD15: 
It is also referred to as Lewis X antigen, X hapten, Leu M1 and 
myelomonocytic marker.[21][27] It is a cell adhesion molecule and its expression 
is seen on the cell membrane of RS cells of classical HL with or without dot like 
golgi localization.[27] CD15 is positive only in a part of HL and its expression is 
believed to have a better prognosis. Certain B and T cell lymphomas may also 
be positive for CD15 and ALCL is always negative for CD15. Its expression is 
confined to the lymphomas and is noted in other cells like granulocytes, 
histiocytes and other non hematolymphoid tissues like breast, proximal 
convoluted tubules of kidney, lung and Paneth cells in GI tract.[29] 
CD30: 
CD30 is also referred to as Kil, Ber H2 and lymphocyte activation antigen.[21] It 
belongs to TNF receptor superfamily and is always positive in classical HL and 
ALCL. CD30 mediated NFkB activation is believed to be the pathophysiology 
behind classical HL.[30][31] It is seen as a membranous positivity with or without 
dot like golgi localization. The followingtable (table 5) summarizes the 
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expression of the commonly used CD markers in various situations and the 
subcellular site of positivity. 
TABLE 5: CD MARKERS WITH THE STAINING PATTERN AND 
POSITIVE CELLS 
MARKERS SITE OF POSITIVITY COMMONLY 
POSITIVE CELLS 
CD45  Membrane  All leucocytes except 
plasma cells 
CD3 Membrane T cells 
CD20 Membrane  B cells 
CD15 Membrane with or 
without golgi positivity 
RS cells, activated T 
lymphocytes , proximal 
convoluted tubules of 
kidney, Paneth cells, 
tumours of lung, breast , 
thyroid and GIT  
CD30 Membrane with or 
without golgi positivity 
RS cells, ALCL, 
activated B cells and 
monocytes 
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In addition to the available wide range of CD markers for determining the 
lineage of lymphomas, there are other markers which are specific for the 
lineage. PAX5 is one such marker which is expressed exclusively in B cells.  
PAX5: 
PAX stands for paired box. The PAX proteins are all transcription factors that 
usually determine the fate of the cells during the early stages of development 
and maturation mostly during embryogenesis and sometimes even in the adult 
life. They are closely related proteins and are called paired box as they have a 
paired domain for binding to the DNA .Genes encoding the PAX proteins are 
called PAX genes. There are about nine PAX genes identified till date.[4] 
PAX5 is otherwise called B cell specific activator protein (BSAP). It is named 
so because of its exclusive expression in B lymphoid lineage. It is a 
transcription protein like other PAX proteins and its expression is noted as early 
as pro B cell stage and is lost during the plasma cell stage.[4] (Figure 7) PAX5 
drives the cells into B cell lineage and hence plays an essential part in B cell 
development. The genes that encode the PAX5 is situated in the chromosome 
9p31. 
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PAX5 suppresses the J chain and XBP1, thereby preventing the cells from 
maturing into plasma cells. Thus BSAP is not only essential in driving the cells 
towards B cell lineage, but also retaining its identity. [33] PAX5 along with 
PAX2 and PAX8 has been demonstrated to influence the apoptosis and aid in 
survival of the cell in nematodes. Hence they are believed to have a role in 
survival of the B cells. [34] 
The suppression of PAX5 is mandatory for plasma cell differentiation. This is 
achieved through increased expression of B lymphocyte induced maturation 
protein 1 (Blimp 1), which is induced by various cytokines. Blimp1 suppress the 
expression of PAX5 in addition to other genes like C-myc. [33] Following 
diagram (fig 8) illustrates the role of PAX5 in B cell development and the 
mechanism by which BLIMP 1 drives the cells towards plasma cell 
differentiation 
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Figure 8: The role of PAX5 in B cell development and the mechanism by 
which BLIMP 1 drives the cells towards plasma cell differentiation 
 
Though immunohistochemical expression of PAX5 is noted in all stages of 
maturation the intensity of staining varies in subsets of B cells. Krenacs et al 
observed a strong PAX5 immunoreactivity in the cells of the marginal zone as 
opposed to the follicular centre cells and monocytoid B cells. [35] 
PAX5, in addition to the B lymphocytes is also observed in CNS during the 
early stages of maturation and in adult testis. [4]  In contrast to these findings, 
Tarlakovic et al observed an absent immunohistochemical reaction of PAX5 in 
adult testis and a positive immunoreactivity in certain parts of the adult brain 
tissue like gray matter of mid brain, neurons of the area postrema, medulla 
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oblongata and a few cells in the caudal nucleus. PAX5 is strongly expressed in 
mesonephric rests of epididymis and smooth muscle cells of uterus. Rare cells 
in prostatic glands and endocervical glands express PAX5 weakly. [36] Thus in 
addition to B cell development and CNS development, PAX5 is thought to play 
a role in urogenital development. 
The various types of B cell lymphomas are believed to represent the cells of 
different stages of maturation.[15][23] PAX 5 expression is noted in majority of 
mature B cell lymphomas, premature B cell lymphomas and HL. They show a 
sharp nuclear reactivity making the assessment of immunoreactivity easy since 
they are devoid of background staining. Being a nuclear antigen, their 
immunoexpression is altered with poor tissue preservation. [5] 
The main utility of PAX5 is its expression in B cell lymphomas which lack or 
show equivocal immunoreactions with the commonly used IHC markers in 
paraffin embedded sections like CD20. CD20 expression is usually absent in 
classic HL and precursor lymphoid neoplasms. The surface CD20 expression is 
lost in patients following Rituximab therapy as it is a targeted therapy against 
CD20. In case of relapse in these patients, the cells may remain to be negative 
for CD20. PAX 5 helps in situations like these to establish the cell lineage. 
Though PAX5 expression is seen in most of the cases of both classical HL and 
NLPHL, the intensity of staining is weak in a majority of the cases. Some cases 
of HL can be negative for PAX5 especially in cases of nodular sclerosis type of 
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classical HL. This reduced expression is due to the down regulation of PAX5 
along with other transcription factors and surface antigens. Blimp1 has been 
observed to be expressed in certain classical HL. This is thought to be the 
reason behind the reduced expression of PAX5 in some cases and even for the 
absence of PAX5 reaction in some cases.[5] 
The expression of PAX5 is absent in a few but a significant number of cases of 
lymphomas with large cell morphology like DLBCL. A study by Torlakovic et 
al showed PAX5 was positive in about 96% of cases, of which 90% showed 
strong positivity. These findings correlated with the immunoexpression of 
CD20. [38] Therefore though, PAX5 is negative in few cases of DLBCL, it is 
equivalent to CD20 in its ability to recognize DLBCL. The weak or absent 
immunoreativity with PAX5 in DLBCL may be because they represent the post 
follicular cells in normal B cell development. [35] 
T cell lymphomas are consistently negative for PAX5. Its expression in T cell 
lymphomas was observed very rarely by different authors.[39][40][41] These cases 
are thought to represent the aberrant or over expression of PAX5 in these 
tumors and Feldman et al observed extra copies of the PAX5 genes in such 
cases. Over expression of PAX5 is observed to induce T cell lymphomas in 
experimental animals. Hence PAX5 was postulated in tumorigenesis of these 
cases. 
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Problems can arise in differentiating between DLBCL, ALCL and HL as all 
these lymphomas can show large cells closely resembling RS cells. The 
routinely used IHC markers can add on to the confusion as these tumors can 
have similar immunophenotypes. Browne et al used PAX5 along with other B 
cell transcription factors oct2, BOB1 and other pan B cell antigens in known 
cases of ALCL, DLBCL and HL. PAX5 was observed to be negative in all the 
cases of ALCL and positive in all cases of DLBCL and NLPHL. It was positive 
in about 91% of classical HL.[42] The negative reaction of PAX5 in T cell 
lymphomas can be exploited in situations like these. 
The expression of PAX5 has also been observed in acute leukemia, both acute 
myeloid leukemia (AML) and acute lymphoid leukemia (ALL). PAX5 positive 
cases of AML mostly belonged to AML with t (8: 12) subtype, but cases of 
AML belonging to other subtypes also showed positive reaction in a few 
instances. AML with t (8:12) is known to express CD19, which is regulated by 
PAX5 and hence its expression is these cases. The number of PAX5 positive 
cases in this subtype of AML varied among different studies. Sarah E Gibson et 
al observed PAX5 being expressed in about 44% of this subtype of AML, [43] 
whereas Joe R Vulbueva et al observed PAX5 expression in all the cases of this 
subtype included in his study. [44] In both the studies the blasts showed weak 
positivity when compared to the adjacent normal B cells. Zhang et al studied the 
expression of PAX5 various NHL and leukemia and concluded that though 
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PAX5 expression is noted in leukemia, their value in classifying these leukemia 
was minimal.[39] 
Though the common understanding is that the PAX5 expression is lost in 
plasma cells differentiation, Pein Lim et al demonstrated PAX5 
immunoexpression in a few cases of multiple myeloma. They were then 
suggested to be retained products of early stages of maturation. [45] 
In addition to the lymphoid cells, neuroendocrine tumors also show positive 
PAX5 expression. [5][36] It is negative in case of carcinoid tumors but is positive 
in a high proportion of Merkel cell carcinomas and small cell carcinomas. The 
other non hematopoietic tumor that shows PAX5 expression is transitional cell 
carcinoma of urinary bladder.[46][47] The expression of PAX5 in these cases was 
found to be inversely proportional to the level of differentiation and directly 
proportional to the stage.[47] This increased expression of PAX5 in more 
aggressive forms suggests they have a prognostic value. PAX5 expression is 
noted in CNS tumors like medulloblastomas, astrocytomas, neuroblastomas etc. 
[48][49] Rare expression of PAX5 was noted by Tarlakovic et al and Paulette et 
al.[36][50] 
The aberrant expression of PAX5 in tumors like neuroendocrine carcinomas, 
transitional cell carcinomas, some CNS tumors and T cell lymphomas indicate a 
possible role of PAX5 in tumorigenesis. Stewart et al proposed that the PAX5 
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suppresses the transcription of p53, a tumor suppressor gene and thereby 
leading to development of the tumor.[48]   
The translocation t (9;14) involving the PAX5 region is found to be linked to 
lymphoplasmacytic lymphoma, further implying the role of PAX5 in 
tumorigenesis.[51] Balasenthil et al postulated that regulation of PAX5 by 
metastasis associated protein (MTA1) lead to its over expression and lymphoma 
genesis.[52] 
Gilles A Roubischad et al identified   about five isoforms of PAX5 from normal 
and lymphoma cells. They observed that all these isoforms had different 
sequence and transactivation properties. PAX5 FL isoform was noted 
predominantly in the lymphomas. Thus this altered form of PAX5 may be the 
reason behind the development of lymphoma in these cases. Moreover the 
oncogenic role of PAX5 in certain T cell lymphomas has been demonstrated in 
mice.[53] 
The high expression of PAX5 in lymphomas, certain non haematolymphoid 
malignancies and its possible role in the development of these tumours have 
encouraged the investigators to develop a targeted therapy against PAX5. 
Mengyong et al have managed to generate a cytotoxic T lymphocyte lines 
against a sequence referred to as TLP on the PAX5 peptide. They observed a 
significant growth restriction and destruction of tumour cells expressing high 
PAX5 in mice. Though the in vivo testing has not been done in humans PAX5 
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poses to be an ideal target for immunotherapy in patients having tumors with 
aberrant expression of PAX5.[54] 
In spite of its expression in various non haematolymphoid tissues and tumors 
PAX5 is still an excellent marker for B cell lineage. Paulette et al and Kirsten et 
al observed a highly specific immunoexpression of PAX5 in B cell 
lymphomas.[50][6] Neuroendocrine carcinomas were the only other tumours that 
which showed high reactivity with PAX5 next to lymphomas. Less than 1% of 
carcinomas showed immunoreactivity with PAX5. 
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MATERIALS AND METHODS 
All the cases diagnosed as lymphomas from January 2009 to December 2010 in 
the department of pathology, PSG institute of medical science and research, 
Coimbatore were considered in the study. The cases with inadequate tissue for 
performing Immunohistochemistry were then excluded from the study. 
The clinical data required for the study like the age, sex, site and stage of the 
tumor were retrieved from the medical records department of PSG institute of 
medical science and research after obtaining permission from the concerned 
authorities and institute human ethics committee clearance. The hemotoxylin 
and eosin slides of these cases were analysed for assessing the morphology and 
also typing.  
The immunohistochemical slides which were used for classification of the 
lymphomas were also retrieved and analyzed. The common panel of markers 
included was CD45, CD3, CD20, CD15 and CD30. These were run for routine 
diagnostic reasons in the department. A few cases were the panel was not 
complete was completed during the study period. Paraffin blocks of those 
sections which had high tumor density were included for the study by reading 
the H and E slides. Blocks of slides which had less tumor material or extensive 
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necrosis were excluded. The following flowchart (figure 9) depicts the study 
plan . 
Fig 9:  THE STUDY PLAN 
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Immunohistochemistry was done using the supersensitive HRP detecting 
system. The following table (table 6) shows the clones of the various primary 
antibodies used during the study  
TABLE 6: The markers, clone of the primary and controls used 
MARKERS COMPANY CLONE CONTROL 
CD45 Biogenex PD7/26/16 Lymphnode 
CD3 Biogenex PSI Lymphnode 
CD20 Biogenex L-26 Lymphnode 
CD15 Biogenex BRA4F1 Kidney 
CD30 Biogenex HRS-4 Hodgkin’s 
lymphoma 
PAX5 Dako DAK Tonsil 
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The procedure for Immunohistochemistry was similar for all the markers and it 
is as follows.[19] 
PRINCIPLE:  In an immunohistochemical reaction , the specific antigen present 
in the cells and tissues was detected in a two stage process, (Figure 10) that 
includes: 
1) The binding of the primary antibody to its specific epitope in the tissues. 
2) Detection of this bound antibody using a dextran polymer bound secondary 
antibody in a calorimetric reaction that involves a chromogen.  
In this method, primary antibody to the specific antigen is first added and is then 
followed by the addition of a dextran polymer linked to multiple conjugated 
secondary antibodies and horse raddish peroxidase enzyme. This multiple 
secondary antibodies bound to the primary antibody and the signal is amplified by 
the use of a suitable chromogen 3, 3’diaminobenzidine tetra hydrochloride (DAB). 
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FIGURE 10: PRINCIPLE OF IHC USING HRP KIT 
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STEP 1: 
Antigen retrieval: 
This is a process to unmask the epitopes of the specific antigens that are masked 
by cross linking action of formalin during routine processing. There are various 
methods for antigen retrieval. The methods include, 
1) Pressure cooker method 
2) Microwave method 
3) Proteolytic digestion method 
Of the above, the pressure cooker method is used for the present study. Here, the 
tissue is exposed to the additive effects of both heat and pressure thereby 
bringing out the full antigenicity. After dewaxing and dehydrating in graded 
alcohols, the slides were subjected to antigen retrieval in a pressure cooker for 
10 minutes with EDTA buffer at pH 9. 
Reagents used: 
¾ EDTA buffer at pH 9 
¾    3% hydrogen peroxide ( H2O2) in distilled water - To block endogenous 
peroxidase activity inorder to prevent nonspecific background staining 
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¾  0.01M  Phosphate buffered saline (PBS) with a pH value of 7.6. It was prepared 
by dissolving the following substances in 1000 ml of distilled water. 
1.Na2HPO4 Dibasic sodium phosphate, anhydrate              17.5g 
2.KH2PO4 Monobasic potassium phosphate, anhydrous     2.5g  
3.NaCl Sodium chloride                                                        17.0g  
¾ Blocking reagent- casein in PBS with 15mM sodium azide. This was used to 
blocks non specific protein binding. 
¾ Step 2: 
¾ Primary antibodies. All the primary antibodies used in the study were in ready 
to use formulation  
¾ Step 3: 
¾ Poly HRP reagent- anti-mouse and anti-rabbit IgG complex linked to Horse 
radish peroxidase enzyme. 
¾ Step 4: 
¾ DAB (3, 3’Diamino Benzidine tetra hydrochloride) - Chromogen. 
       It offers great sensitivity as an HRP calorimetric chromogen and provides 
insoluble permanent coarse brown precipitate. 
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Step 5 
¾ Harris hematoxylin as counter stain. 
¾ DPX (Distrene dibutyl phthalate Xylene) - Mountant. 
PROCEDURE: 
 Immunohistochemical Staining with the two specific antibodies were done as 
follows         
• Slides were deparaffinised 
• deparaffinised slides were hydrated using graded alcohol. 
• Antigen retrieval: using EDTA buffer at pH 9.0 in a pressure cooker for 10 
minutes. 
• Fast cooling under tap water. 
• Washed in PBS buffer at pH 7.6 for for 5 minutes 
• After wiping off excess PBS buffer the slides were immersed in 0.3% H2O2 for 
20 minutes to block endogenous peroxidase activity. 
•  Washed in PBS buffer thrice, each 5 minutes 
•  Slides were incubated in blocking solution for 10 minutes to block non-specific 
protein binding. 
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•  Washed in PBS buffer thrice , each 5 minutes. 
•  Slides were incubated with the primary antibody for 1 Hr. 
•  To enhance the signal intensity, the sections were put in superenhancer for 30 
minutes. 
•  Washed in PBS buffer thrice, each 5 minutes. 
•  Horse radish peroxidase polymer reagent was added to the slide and incubated 
for 30 minutes. 
•  Washed in PBS buffer thrice, each 5 minutes. 
• Chromogen Diamino Benzidine (DAB) was applied for 8 minutes. 
•  Washed in PBS buffer thrice, each 5 minutes. 
•  Sections were counter stained with Harris hematoxylin for 1 minute. 
•  Washed in tap water. 
Sections  were cleared in Xylene and mounted with DPX mountant. 
These sections were than assessed for the immunoreactivity. All the CD markers 
were considered positive when they showed a membranous positivity in the 
neoplastic cells. Slides stained with PAX5 immunohistochemistry were 
considered positive when they show a brisk nuclear positivity. Less than 10% of 
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cells showing positivity were considered negative. The intensity of the staining 
was also considered. 
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 Figure 11: Algorithm of the steps involved in running Immunohistochemistry 
                          
 
                                                                      
                        
 
 
                           
 
 
 
  
          
  
 
     Tissue Preparation and antigen retrieval 
Step 2 
Primary antibody 
Step 3 
         Secondary antibody 
Step 4          DAB – chromogen application 
Step 5          Counter stain and mount 
Step 1 
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RESULTS 
 
The department of pathology, PSG institute of medical science and research has 
received 8207 biopsy specimens over a period of two years from 1st January 2009 to 31st 
December 2010. The total number of malignancies reported during the study period was 
922. Out of these 922 cases, 59 cases were reported as malignant lymphomas giving an 
overall incidence of 6.3%. Table 7 shows the no of malignancies reported each year and 
the incidence of lymphomas for the year 2009 and 2010. 
 
 
YEAR 
 
NO: OF 
MALIGNANCIES
 
NO:OF 
LYMPHOMAS 
 
INCIDENCE 
RATES 
2009 443 30 6.7 
2010 479 29 6.0 
TOTAL 922 59 6.3 
 
    Of the 59 cases reported as lymphomas during the study period, 19 cases were not 
included in the study owing to inadequate tissue samples and unavailability of tissue 
blocks. The remaining 40 cases include 28 nodal lymphomas and 12 extra-nodal 
lymphomas of which 33 were non Hodgkin’s lymphoma and 7 were Hodgkin’s 
lymphoma. Most of the non Hodgkin’s lymphomas were of B cell type. 4 out of the 33 
non Hodgkin’s lymphomas were not classified under a specific cell type and were 
TABLE 7:   Incidence of lymphomas during the study period 
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The age group ranged from 3 years to 75 years, with a mean age of 43.5 years. 5 out of 
7 cases of Hodgkin’s lymphoma were in the second and the fifth decades. 18 out of the 
33 cases of non hodgkins lymphoma were in the sixth and seventh decade of life.  
Table 9 shows the age wise distribution of various lymphomas. 
Table 9- Distribution of various lymphomas age wise 
AGE HL NHL 
B CELL  T CELL UNCLASSIFIED
0-10 1 0 1 1 
11-20 3 1 1 0 
21-30 0 0 2 0 
31-40 0 0 0 1 
41-50 2 5 1 0 
51-60 0 6 1 0 
61-70 1 8 2 1 
>70 0 1 0 1 
TOTAL 7 21 8 4 
 
Of all the 40 cases, 28 were males and 12 were females, giving rise to a male: female 
ration of 2.3:1. All the cases of Hodgkin’s lymphoma were males. B cell type non 
Hodgkins lymphoma were more common than the T cell type non Hodgkin lymphoma 
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Sections of lymphomas were stained with the immunohistochemical markers, 
commonly used in the diagnosis of lymphomas which includes CD45, CD3, 
CD20,CD15,CD30. They were studied and determined whether positive or negative. 
Areas staining the reactive lymphoid cells were excluded. 
All the cases except one were positive for CD45. This case had the following 
immunoprofile – CD45-ve, CD3-ve, CD20-ve, CD15-ve, CD30+ve and EMA+ve. 
Based on the morphology and the immunoprofile, it was diagnosed as anaplastic large 
cell lymphoma, a T/NK cell non Hodgkin’s lymphoma. 
The Reed-Sternberg cells of all the cases of Hodgkin’s lymphoma were positive for 
CD15, CD30 (figure 13 to 15) and negative for CD3, CD20. This is the immunoprofile 
for classical Hodgkin’s lymphoma. 
Among the non Hodgkin’s lymphoma, 7 were positive for CD3, 21 were positive for 
CD 20 and 4 were negative for both CD3 and CD20. Lymphomas positive for CD20 
were classified as B cell non Hodgkin’s lymphoma, those positive for CD3 were 
classified as T cell non Hodgkin’s lymphoma and others were placed under unclassified 
category. Table 13 shows the number of cases in each immunoprofile. 
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Table 13 – IHC analysis of commonly used antibodies in the diagnosis of 
lymphomas 
IMMUNOPROFILE NO OF CASES 
HL (CD 15 +VE, CD 30 +VE) 7 
NHL(CD 15 –VE, CD 30 –VE) 
-CD 3 +VE 7 
-CD20 +VE 21 
-CD 45 +VE, CD 3 –VE, CD 20 –VE 4 
-CD 45 –VE 1 
 
All the cases were stained with PAX5 antibody and its expression in different age 
groups, sex, site, stage and types of lymphomas. A strong nuclear staining was 
considered positive. 
23 out of the 40 cases were positive for PAX5. PAX5 was negative in all T cell non 
Hodgkin’s lymphoma and the cases under the unclassified category. Out of 21 cases of 
B cell non Hodgkin’s lymphoma, 18 were positive. Reed-Sternberg cells of Hodgkin’s 
lymphoma were positive in 5 cases. (figure 16) Table 14 shows the expression of PAX5 
in various lymphomas . 
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Table 14 – expression of PAX5in various lymphomas 
TYPE OF 
LYMPHOMA 
NO OF CASES PAX 5 +VE PAX 5 –VE 
HL 7 5 2 
NHL 33 18 15 
-B CELL TYPE 
NHL  
21 18 3 
-T CELL TYPE 
NHL 
8 0 8 
-UNCLASSIFIED 4 0 4 
 
PAX5 was positive in 17 out of 28 nodal lymphomas. This 17 cases consists of 5 cases 
of  Hodgkins lymphoma and 12 cases of  B cell type non Hodgkins lymphoma. Among 
the 12 extranodal lymphomas, 7 were of  B cell type non Hodgkins lymphoma. PAX5 
was positive in 6 of them. (figure 17 to20)Table 15 shows PAX5 expression in relation 
to site and type the of lymphoma. 
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Table 15 – Expression of lymphomas in relation to site and type of lymphoma 
    TOTAL  NO  OF 
CASES 
PAX 5 +VE CASES
NODAL 
LYMPHOMAS 
HL  7 5
B CELL NHL 14 12 
T CELL NHL 5 0
UNCLASSIFIED 2 0
EXTRA  NODAL 
LYMPHOMAS 
HL  0 0
B CELL NHL 7 6
T CELL NHL 3 0
UNCLASSIFIED 2 0
 
The expression of  PAX5 in females and males were assessed. PAX5 was positive in 17 
out of 28 male cases and 6 out of 12 female cases. All the B cell type non Hodgkins 
lymphoma of females were positive for PAX5. PAX5 was negative in 2 cases of 
Hodgkins lymphoma and 3 cases of  B cell type non Hodgkins lymphoma of male.  
Table 16 shows the expression of PAX5 in relation to sex 
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Table 16 – Expression of PAX5 in relation to sex 
SEX HL PAX 5+VE 
HL 
B CELL 
TYPE NHL 
PAX5 +VE B 
CELL TYPE 
NHL 
MALES 7 5 15 12 
FEMALES 0 0 6 6 
 
 PAX5 expression in relation to age was studied and table 17 shows the observations in 
the expression of PAX5 in various age groups 
Table 17- Expression of PAX5 in relation to age 
AGE  HL   PAX 5 +VE 
HL 
 B CELL 
TYPE NHL 
 PAX 5 +VE 
B CELL 
TYPE NHL 
0-10 1 1 0 0 
11-20 3 1 1 0 
21-30 0 0 0 0 
31-40 0 0 0 0 
41-50 2 2 5 5 
51-60 0 0 6 4 
61-70 1 1 8 8 
>70 0 0 1 1 
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PAX5 expression across various stages was assessed. PAX5 was positive in most of the 
B cell non Hodgkin’s lymphoma and Hodgkin’s lymphoma regardless of the stage. 
Table 18 – expression of PAX5 across various stages 
STAGE  HL  B CELL TYPE NHL PAX 5 +VE CASES
I  1  6 7
II  1  6 6
III  1  4 3
IV  4  3 6
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DISCUSSION 
 
Malignancies constituted 11.2 % (922/8207) among all biopsies reported from 
PSGIMSR during the period of study. Lymphomas constituted 6.3% of all 
malignancies in this institute which is significantly higher than that reported in 
the western literature (3%) and from the Chennai (4.25%) as reported in the 
national cancer registry atlas in the year 2001- 2003. [2]This increase in 
incidence observed in this institute could be due to the fact that this hospital is a 
tertiary care referral centre and is equipped with better diagnostic facilities. 
However an epidemiological survey and survey of lymphoma registry of the 
region is essential for proving the increased incidence noted in our study. 
In B cell development, activation and differentiation PAX5 plays a crucial role 
especially when the neoplasm is both CD3 and CD20 negative. [38] Pax5 is 
expressed in all B cells except the terminal B cell population including the 
plasma cells. 
Many studies quote that a significant number of cases which are CD20 negative 
express PAX5. A study done by Torlakovic et al states that PAX5 transcription 
factor expression studies play a vital role in the diagnosis. [38] 
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With the increase in the incidence of lymphomas globally an  increased 
incidence observed in our institute prompted us to carry out this study on the 
significance of PAX5 expression in lymphomas.  
We identified and retrieved 40 cases of lymphomas from the archives of 
pathology using the inclusion and exclusion criteria as discussed earlier. Most 
of the cases included in our study had the basic diagnostic panel of routine 
markers run for subtyping into B using CD20 and T cell type using CD3 / 
Hodgkin disease. 
We had 7 cases of Hodgkin lymphoma and 33 cases of non Hodgkin lymphoma. 
Out of these 33 cases of non Hodgkin lymphoma 21 were from nodal and 12 
cases were from extra nodal sites. 
21/33 cases of NHL were of B cell type,8 were T cell type and 4  were 
unclassified.4 unclassified over 33 is a significant number and as the treatment 
and prognosis depends on the type of lymphomas an additional marker like 
PAX 5 is essential to identify the pre B cell types which are CD20 negative. 
The peak age incidence of lymphoma observed in our study is 5th to 7th decade 
and is similar to all other studies. Though PAX 5 expression does not have a 
significant correlation with the age at presentation it is noteworthy to observe 
that the 2 cases of lymphomas (1 B cell and 1 unclassified) were negative. As 
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the numbers are small a larger prospective study on PAX5 in correlation with 
the age is essential. 
In our study comprising 40 cases there was a slight male preponderance (28 
males and 21 females) with a ratio of 1.3:1 which is very similar to the 
literature. 
 
An equal distribution of lymphomas were seen across the stages I, II and, III 
except stage IV, where we had 7 out of 40 cases. PAX 5 was expressed in 23 
out of forty cases and therefore Pax5 expression is not stage dependent. All the 
CD3 positive cases were PAX5 negative which was as expected.  
Out of the 21 CD20 positive cases only 18 cases where PAX5 positive and 3 
cases were PAX5 negative. This negativity could be due to terminal B cell 
differentiation.  We also observed in DLBCL a weak expression of PAX5  
which is in correlation with the other studies. Out of the 7 cases of HL 5 
expressed positivity with PAX5 . The literature states that HL usually shows a 
weak positivity with PAX5, but in our study 4 out of the 5 cases which 
expressed pax5 showed a strong intense reaction and in increased number of 
cells. As in most of the cases, the entire node is submitted for routine analysis; 
sampling error is highly unlikely in these cases. The strong reaction could be 
due to a neoplastic clone, which expresses increased PAX5 transcription factor 
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in our population. However the number of samples in our study is minimal, and 
hence a further larger study exclusively in HL is essential. 
In conclusion , the analysis from our study showed there is a twofold increase in 
incidence of lymphoma in this institute when compared to the referred 
literature. NHL was more common than HL and the B cell phenotype was the 
commonest. Pax 5 had no significant correlation with age, sex or stage of the 
disease. 3 of the CD20 positive cases did not express PAX5, which could be due 
to a terminal B cell differentiation. We also found that in our study we showed 
that HL had a strong reaction to PAX5 when compared to other studies in the 
literature. 
As our study showed a strong expression of PAX5 in HL, a larger study on 
PAX 5 expression in HL is vital to look for an increased expression in subset of 
Indian population. 
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Fig 12: Algorithm of the study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
   
Total number of lymphomas during the study period: 59 
                   
        Selected cases: 40 
HL – 7 
CASES 
    21 B CELL    8 T CELL
Exclusion of 19 cases 
NHL‐39 CASES 
4 UNCLASSIFIED
IIMMUNOHISTOCHEMISTRY USING PAX 5 WAS DONE 
5 POSITIVE  AND 2 NEGATIVE HL 
18 POSITIVE AND 3NEGATIVE B NHL
ALL NEGATIVE T CELL AND UNCLASSIFIED
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CONCLUSION AND SUMMARY 
In conclusion our study on lymphomas reported from PSGIMSR from January 
2009 to December 2010 revealed a 6.3% incidence which is 3% higher than that 
reported in the literature. Out of these 40 cases 17% were HL and 83% were 
NHL. We also infer that most of the B cell neoplasms expressed PAX5 as 
reported in the literature. Three cases of proven B cell neoplasms were PAX5 
negative. This probably could be because of terminal differentiation in these 
cases. We also observed in our study, that 4 out of the 5 cases of HL which 
were positive for PAX5 showed a strong intense staining of nucleus with PAX5. 
A larger prospective study is essential to identify a subset of HL with increased 
PAX5 expression.  
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 Fig17: Nodal B cell lymphoma (H&E, 
40X) 
Fig18: A strong membranous 
positivity with CD20 (IHC,40X) 
 
Fig19: Negative staining with CD3 
NHL (IHC, 40X) 
 
Fig20: A strong intense nuclear 
staining with PAX5 in  a case of B 
cell NHL (IHC, 40X) 
  
Fig13: Classical HL (H&E, 40X). 
Inset shows a classical RS cell 
Fig14: RS cells showing a faint 
membranous positivity and a 
paranuclear dot like positivity 
with CD15  (IHC, 40X) 
Fig15: RS cells showing a strong 
membranous positivity and a 
paranuclear dot like positivity with 
CD30 (IHC, 40X) 
Fig16: RS cells showing a strong 
nuclear positivity with PAX5 (IHC, 
40X) 
  
Fig21: T cell  NHL (H&E, 40X) 
 
Fig22: A strong membranous 
positivity with CD3 in a case of T cell 
NHL (IHC, 40X) 
Fig23: Negative staining with CD20 
in a case of T cell NHL (IHC, 40X) 
 
Fig24: Negative staining with PAX5 
in a case of T cell NHL (IHC, 40X) 
 
LIST OF ABBREVATIONS 
 
ALCL –Anaplastic large cell lymphoma  
BSAP – B cell specific activator protein 
CD - Cluster of differentiation 
CHL - Classical Hodgkin’s lymphoma 
DLBCL – Diffuse large B cell lymphoma 
 HL – Hodgkin’s lymphoma 
HD – Hodgkin’s disease 
IHC – Immunohistochemistry  
LCA – Leucocyte common antigen 
NHL – Non Hodgkin’s lymphoma 
NLPHL – Nodular lymphocyte predominant Hodgkin’s lymphoma  
PAX5 - Paired box 5 
RS cells – Reed Sternberg cells 
WHO – World health organisation 
 
S.NO  BIOPSY 
NO. 
AGE   SEX  CD 45  CD 3  CD 20  CD 15  CD 30  PAX 5  REPORT  SITE  STAGE 
1  451/09  9  F  +  +  ‐  ‐  ‐  ‐  T‐LYMPHOBLASTIC 
LYMPHOMA 
AXILLARY LYMPH 
NODE 
III 
 
2   673/09  61  F  +  ‐  +  ‐  ‐  +  NHL  LYMPH NODE  I 
3  1048/09  61  M  +  ‐ + ‐ ‐ + NHL  LYMPH NODE IN 
PAROTID 
II
4  1332/09  48  M  +  ‐ ‐ + + + HL CERVICAL 
LYMPHNODE 
IV
5  1896/09  75  F  +  ‐ ‐ ‐ ‐ ‐ NHL  CERVICAL 
LYMPNODE 
III
6  2444/09  60  M  +  + ‐ ‐ ‐ ‐ ANGIOIMMUNOBLASTIC T 
CELL LYMPHOMA 
LEFT INGUINAL 
LYMPH NODE 
III
7  2445/09  56  F  +  ‐  +  ‐  ‐  +  SPLENIC MARGINAL ZONE 
B CELL LYMPHOMA 
SPLEEN  I 
8  3482/09  55  M  +  ‐  +  ‐  ‐  ‐  B CELL LYMPHOMA  SKIN  NA 
9  3907/09  44  F  +  ‐ + ‐ ‐ + NHL  FALLOPIAN TUBE II
10  4030/09  53  M  +  ‐ + ‐ ‐ ‐ DIFFUSE B CELL NHL ABDOMINAL MASS III
11  4061/09  42  F  +  ‐  +  ‐  ‐  +  NHL  OROPHARYNX  NA 
12  4275/09  55  M  +  ‐  +  ‐  ‐  +  NHL, MANTLE CELL 
LYMPHOMA 
TONSILS  II 
13  4281/09  62  M  +  ‐  +  ‐  ‐  +  DIFFUSE LARGE B CELL 
LYMPHOMA 
SUPRACLAVICULAR 
LYMPH NODE 
II 
14  4424/09  3  F  +  ‐  ‐  ‐  ‐  ‐  LYMPHOMA  CERVICAL LYMPH 
NODE 
II 
15  4647/09  63  M  +  ‐  +  ‐  ‐  +  LYMPNOMA  RETROPERITONEAL 
MASS 
I 
16  4892/09  48  F  +  ‐  +  ‐  ‐  +  DIFFUSE LARGE B CELL 
LYMPHOMA 
AXILLARY LYMPH 
NODE 
IV 
17  154/10  4  M  +  ‐  ‐  ‐  ‐  ‐  SMALL  ROUND CELL 
TUMOUR 
MAXILLARY MASS  III 
 
 
18  519/10  18  M  +  ‐ + ‐ ‐ ‐ LYMPNHOMA MEDIASTINAL 
MASS 
IV
19  585/10  66  M  +  ‐ + ‐ ‐ + MALTOMA  GASTRIC BIOPSY I
20  852/10  47  F  +  ‐  +  ‐  ‐  +  DIFFUSE LARGE B CELL 
LYMPHOMA 
CAECUM,BIOPSY  II 
21  902/10  75  M  +  ‐  +  ‐  ‐  +  SMALL LYMPHOBLASTIC 
LYMPHOMA 
AXILLARY LYMPH 
NODE 
III 
22  971/10  50  M  +  +  ‐  ‐  ‐  ‐  T CELL LYMPHOMA  CERVICAL LYMPH 
NODE 
I 
23  1254/10  43  M  +  ‐  +  ‐  ‐  +  FOLLICULAR LYMPHOMA  POSTERIOR 
TRIANGLE LYMPH 
NODE 
IV 
24  1489/10  19  M  +  ‐  ‐  +  +  +  HODGKINS LYMPHOMA  CERVICAL LYMPH 
NODE 
IV 
25  1567/10  65  M  +  ‐  +  ‐  ‐  +  MANTLE CELL LYMPHOMA  CERVICAL LYMPH 
NODE 
I 
26  1690/10  16  M  +  ‐  ‐  +  +  ‐  HODGKINS LYMPHOMA  SUPRACLAVICULAR 
LYMPH NODE 
III 
27  1760/10  62  F  +  ‐  ‐  ‐  ‐  ‐  NHL  SKIN  NA 
28  1809/10  15  M  +  ‐  ‐  ‐/+  +  ‐  HODGKINS LYMPHOMA  CERVICAL LYMPH 
NODE 
II 
29  1902/10  65  M  +  +  ‐  ‐  ‐  ‐  ATYPICAL LYMPHOID 
CELLS 
SPLEEN  II 
30  2011/10  65  M  +  +  ‐  ‐  ‐  ‐  MYCOSIS FUNGOIDES  SKIN  NA 
31  2336/10  51  M  +  ‐  +  ‐  ‐  +  MANTLE CELL LYMPHOMA  CERVICAL LYMPH 
NODE 
III 
32  2356/10  21  F  +  +  ‐  ‐  ‐  ‐  MYCOSIS FUNGOIDES  SKIN  NA 
33  2849/10  6  M  +  ‐  ‐  +  +  +  HODGKINS LYMPHOMA  CERVICAL LYMPH 
NODE 
IV 
34  3179/10  19  F  ‐  ‐  ‐  ‐  +  ‐  ANAPLASTIC MARGINAL 
ZONE LYMPHOMA 
SUPRACLAVICULAR 
LYMPH NODE 
I 
 
 
 35  3363/10  65  F  +  ‐ + ‐ ‐ + DIFFUSE LARGE B CELL 
LYMPHOMA 
CERVICAL LYMPH 
NODE 
I
36  3375/10  65  M  +  ‐ ‐ ‐ + + HODGKINS LYMPHOMA AXILLARY LYMPH 
NODE 
I
37  3472/10  62  M  +  ‐ + ‐ ‐ + B CELL NHL CERVICAL LYMPH 
NODE 
II
38  3667/10  21  M  +  + ‐ ‐ + ‐ ANAPLASTIC LARGE CELL 
LYMPHOMA 
AXILLARY LYMPH 
NODE 
III
 
39  4074/10  59  M  +  ‐ + ‐ ‐ + B CELL NHL AXILLARY LYMPH 
NODE 
III
40  4279/10  45  M  +  ‐ ‐ ‐ + + HODGKINS LYMPHOMA AXILLARY LYMPH 
NODE 
IV
